United States: The Medicines Company Agrees To Divest Its Hemostasis Portfolio To Mallinckrodt Plc
Last Updated: December 31 2015

On December 18, The Medicines Company (NASDAQ:MDCO) announced that it entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company's global portfolio of three hemostasis products—RECOTHROM® Thrombin topical (Recombinant), PreveLeak", and RAPLIXA" (fibrin sealant)—for a total potential consideration of up to $410 million.

The WilmerHale team representing The Medicines Company was led by Partner Joe Conahan and included Senior Associate Michael Welhouse and Associate Mark Nylen (corporate), as well as Partners Steve Barrett (IP), Robert Burke (tax), Scott Kilgore (labor and employment), Bruce Manheim (regulatory), Hartmut Schneider and Special Counsel Jeffrey Ayer (antitrust).

The formal press release can be found on www.themedicinescompany.com.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Rachel Jacobson, Matthew F. Ferraro, Andrew L. Spielman
By David Gammell
By Jonathan Cedarbaum, D. Reed Freeman, Jr., Alan Schoenfeld, Heather Zachary, Stephanie Simon
By Alan Wilson, Jonathan Wolfman
By Ambassador Charlene Barshefsky, Naboth van den Broek, David Ross, Patrick J. McLain, David Horn
By Frederick Saugman
By Bill Warren
By Michael Connor, H. David Gold, Sarah Judkins, Andrew L. Spielman
By Lester Ross, Tingting Liu
By H. David Gold, Rachel Jacobson, Heidi K. Ruckriegle
Font Size: